Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Advances in Micro/Nanotechnology in Drug Delivery
share announcement

Advances in Micro/Nanotechnology in Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 13440

Special Issue Editor

Dr. Armin Mooranian

E-Mail Website
Guest Editor
Biotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Kent St, Bentley, WA 6102, Australia
Interests: bioengineering; nanotechnology; biomaterials; pharmaceutical technology; clinical research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The field of drug delivery is undergoing rapid advancement via the deployment of micro- and nanotechnology. Previously limited to the fields of engineering with some input to small-scale biologicals, micro/nanotechnology is now seen as pivotal to drug delivery by overcoming barriers to absorption, dissolution, tissue permeation and catering for targeted and controlled delivery of essentially any therapeutic compound. Novel engineering applications using rapid phase drying, vibrational jet flow and drug-based bioprinted microdevices are capable, highly customised delivery platforms, multi-layered designs, highly conformational three-dimensional structures and variable membrane/size structures which cater for controlled, targeted delivery to almost any site within in the human body.

The purpose of this Special Issue of the journal Pharmaceutics is to draw attention and foster a collective cohort approach to the latest concepts in micro/nanotechnology applied to drug delivery.

 Dr. Armin Mooranian
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioengineering
  • biomaterials
  • nanotechnology
  • advanced drug delivery
  • medical biotechnology
  • pharmacology and toxicology
  • pharmacokinetics and pharmacodynamics
  • preclinical research

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 3131 KiB  
Article
Probucol Pharmacological and Bio-Nanotechnological Effects on Surgically Transplanted Graft Due to Powerful Anti-Inflammatory, Anti-Fibrotic and Potential Bile Acid Modulatory Actions
by Armin Mooranian, Corina Mihaela Ionescu, Susbin Raj Wagle, Bozica Kovacevic, Daniel Walker, Melissa Jones, Jacqueline Chester, Thomas Foster, Edan Johnston, Momir Mikov, Marcus D. Atlas and Hani Al-Salami
Pharmaceutics 2021, 13(8), 1304; https://doi.org/10.3390/pharmaceutics13081304 - 20 Aug 2021
Cited by 7 | Viewed by 2162
Abstract
Introduction. A major obstacle in islet transplantation and graft survival pre and post transplantation is islet apoptosis due to mainly inflammatory bio molecules released during islet harvesting and post graft transplantation and hence, subsequent graft fibrosis and failure. This study aimed to investigate [...] Read more.
Introduction. A major obstacle in islet transplantation and graft survival pre and post transplantation is islet apoptosis due to mainly inflammatory bio molecules released during islet harvesting and post graft transplantation and hence, subsequent graft fibrosis and failure. This study aimed to investigate if incorporation of the anti-inflammatory anti-hyperlipidaemic drug probucol (PB) would improve islet-graft survival and function, post transplantation in Type 1 diabetes (T1D). Methods. T1D was induced in mice, and biological profiles of the diabetic mice transplanted PB-microencapsulated islets harvested from healthy syngeneic mice were measured. Results and Conclusion. Compared with sham (no PB), the treated group showed significant reduction in serum levels of interleukin-1β, interleukin-6, interleukin-12, interleukin-17, and tumour necrosis factor-α, accompanied by a 3-fold increase in survival duration, which suggests PB islet-protective effects, post transplantation. Full article
(This article belongs to the Special Issue Advances in Micro/Nanotechnology in Drug Delivery)
►▼ Show Figures

Graphical abstract

28 pages, 5204 KiB  
Article
An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development
by Zsófia Németh, Edina Pallagi, Dorina Gabriella Dobó, Gábor Kozma, Zoltán Kónya and Ildikó Csóka
Pharmaceutics 2021, 13(7), 1071; https://doi.org/10.3390/pharmaceutics13071071 - 13 Jul 2021
Cited by 11 | Viewed by 2517
Abstract
Liposomal formulation development is a challenging process. Certain factors have a critical influence on the characteristics of the liposomes, and even the relevant properties can vary based on the predefined interests of the research. In this paper, a Quality by Design-guided and Risk [...] Read more.
Liposomal formulation development is a challenging process. Certain factors have a critical influence on the characteristics of the liposomes, and even the relevant properties can vary based on the predefined interests of the research. In this paper, a Quality by Design-guided and Risk Assessment (RA)-based study was performed to determine the Critical Material Attributes and the Critical Process Parameters of an “intermediate” active pharmaceutical ingredient-free liposome formulation prepared via the thin-film hydration method, collect the Critical Quality Attributes of the future carrier system and show the process of narrowing a general initial RA for a specific case. The theoretical liposome design was proved through experimental models. The investigated critical factors covered the working temperature, the ratio between the wall-forming agents (phosphatidylcholine and cholesterol), the PEGylated phospholipid content (DPPE-PEG2000), the type of the hydration media (saline or phosphate-buffered saline solutions) and the cryoprotectants (glucose, sorbitol or trehalose). The characterisation results (size, surface charge, thermodynamic behaviours, formed structure and bonds) of the prepared liposomes supported the outcomes of the updated RA. The findings can be used as a basis for a particular study with specified circumstances. Full article
(This article belongs to the Special Issue Advances in Micro/Nanotechnology in Drug Delivery)
►▼ Show Figures

Figure 1

Review

Jump to: Research

61 pages, 12072 KiB  
Review
Nanotechnology as a Versatile Tool for 19F-MRI Agent’s Formulation: A Glimpse into the Use of Perfluorinated and Fluorinated Compounds in Nanoparticles
by Joice Maria Joseph, Maria Rosa Gigliobianco, Bita Mahdavi Firouzabadi, Roberta Censi and Piera Di Martino
Pharmaceutics 2022, 14(2), 382; https://doi.org/10.3390/pharmaceutics14020382 - 09 Feb 2022
Cited by 10 | Viewed by 3096
Abstract
Simultaneously being a non-radiative and non-invasive technique makes magnetic resonance imaging (MRI) one of the highly sought imaging techniques for the early diagnosis and treatment of diseases. Despite more than four decades of research on finding a suitable imaging agent from fluorine for [...] Read more.
Simultaneously being a non-radiative and non-invasive technique makes magnetic resonance imaging (MRI) one of the highly sought imaging techniques for the early diagnosis and treatment of diseases. Despite more than four decades of research on finding a suitable imaging agent from fluorine for clinical applications, it still lingers as a challenge to get the regulatory approval compared to its hydrogen counterpart. The pertinent hurdle is the simultaneous intrinsic hydrophobicity and lipophobicity of fluorine and its derivatives that make them insoluble in any liquids, strongly limiting their application in areas such as targeted delivery. A blossoming technique to circumvent the unfavorable physicochemical characteristics of perfluorocarbon compounds (PFCs) and guarantee a high local concentration of fluorine in the desired body part is to encapsulate them in nanosystems. In this review, we will be emphasizing different types of nanocarrier systems studied to encapsulate various PFCs and fluorinated compounds, headway to be applied as a contrast agent (CA) in fluorine-19 MRI (19F MRI). We would also scrutinize, especially from studies over the last decade, the different types of PFCs and their specific applications and limitations concerning the nanoparticle (NP) system used to encapsulate them. A critical evaluation for future opportunities would be speculated. Full article
(This article belongs to the Special Issue Advances in Micro/Nanotechnology in Drug Delivery)
►▼ Show Figures

Figure 1

18 pages, 2093 KiB  
Review
Dexibuprofen Therapeutic Advances: Prodrugs and Nanotechnological Formulations
by Anna Gliszczyńska and Elena Sánchez-López
Pharmaceutics 2021, 13(3), 414; https://doi.org/10.3390/pharmaceutics13030414 - 19 Mar 2021
Cited by 17 | Viewed by 4513
Abstract
S-(+) enantiomer of ibuprofen (IBU) dexibuprofen (DXI) is known to be more potent than its R-(−) form and exhibits many advantages over the racemic mixture of IBU such as lower toxicity, greater clinical efficacy, and lesser variability in therapeutic effects. Moreover, [...] Read more.
S-(+) enantiomer of ibuprofen (IBU) dexibuprofen (DXI) is known to be more potent than its R-(−) form and exhibits many advantages over the racemic mixture of IBU such as lower toxicity, greater clinical efficacy, and lesser variability in therapeutic effects. Moreover, DXI potential has been recently advocated to reduce cancer development and prevent the development of neurodegenerative diseases in addition to its anti-inflammatory properties. During the last decade, many attempts have been made to design novel formulations of DXI aimed at increasing its therapeutic benefits and minimizing the adverse effects. Therefore, this article summarizes pharmacological information about DXI, its pharmacokinetics, safety, and therapeutic outcomes. Moreover, modified DXI drug delivery approaches are extensively discussed. Recent studies of DXI prodrugs and novel DXI nanoformulations are analyzed as well as reviewing their efficacy for ocular, skin, and oral applications. Full article
(This article belongs to the Special Issue Advances in Micro/Nanotechnology in Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop